Covered recipient · General Payments record
CINDY E OWEN
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$1,014.27
67 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $914.28 | 66 |
| Education | $99.99 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AbbVie Inc. | $400.40 | 27 |
| Janssen Biotech, Inc. | $207.28 | 14 |
| Regeneron Healthcare Solutions, Inc. | $92.62 | 6 |
| GENZYME CORPORATION | $77.10 | 4 |
| Lilly USA, LLC | $66.62 | 5 |
| Novartis Pharmaceuticals Corporation | $62.48 | 4 |
| LEO Pharma Inc. | $48.71 | 3 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $42.86 | 3 |
| DERMIRA, INC. | $16.20 | 1 |
Page 1 of 2; records 1–50 of 67 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
CINDY E OWEN
NPI 1598803819 · CMS profile ID 117868
Allopathic & Osteopathic Physicians / Dermatology
LOUISVILLE, KY
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 2; records 1–50 of 67 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1598803819?year=2021&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- CINDY E OWEN, NPI 1598803819, CMS profile ID 117868. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 67 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598803819?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). CINDY E OWEN, NPI 1598803819, CMS profile ID 117868. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 67 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598803819?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- CINDY E OWEN, NPI 1598803819, CMS profile ID 117868, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 67 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1598803819?year=2021&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
67 matching records · $1,014.27 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–50 of 67.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19.26 | 12/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813134841 | CMS |
| AbbVie Inc. | $14.98 | 12/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795458319 | CMS |
| AbbVie Inc. | $7.70 | 12/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795458313 | CMS |
| Lilly USA, LLC | $12.70 | 12/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819028941 | CMS |
| AbbVie Inc. | $17.84 | 11/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795458307 | CMS |
| AbbVie Inc. | $19.12 | 11/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795458301 | CMS |
| AbbVie Inc. | $20.99 | 11/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795458295 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $15.75 | 11/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849549183 | CMS |
| LEO Pharma Inc. | $21.14 | 11/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842238675 | CMS |
| GENZYME CORPORATION | $21.84 | 11/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843637293 | CMS |
| AbbVie Inc. | $17.51 | 10/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795458289 | CMS |
| AbbVie Inc. | $4.52 | 10/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795458283 | CMS |
| GENZYME CORPORATION | $16.19 | 10/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843637291 | CMS |
| Lilly USA, LLC | $12.34 | 10/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819017609 | CMS |
| AbbVie Inc. | $21.79 | 10/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795458277 | CMS |
| Janssen Biotech, Inc. | $20.03 | 10/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788456905 | CMS |
| Novartis Pharmaceuticals Corporation | $13.39 | 09/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813134837 | CMS |
| AbbVie Inc. | $19.54 | 09/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795458269 | CMS |
| Janssen Biotech, Inc. | $8.99 | 09/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788456900 | CMS |
| LEO Pharma Inc. | $14.81 | 09/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842238665 | CMS |
| AbbVie Inc. | $17.11 | 08/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795458263 | CMS |
| Lilly USA, LLC | $11.21 | 08/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819016691 | CMS |
| AbbVie Inc. | $15.26 | 08/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795458257 | CMS |
| AbbVie Inc. | $7.34 | 08/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795458245 | CMS |
| AbbVie Inc. | $10.94 | 08/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795458251 | CMS |
| GENZYME CORPORATION | $18.86 | 08/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843637253 | CMS |
| Janssen Biotech, Inc. | $9.76 | 08/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788456895 | CMS |
| Lilly USA, LLC | $11.64 | 08/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819018275 | CMS |
| AbbVie Inc. | $7.63 | 07/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795458239 | CMS |
| Regeneron Healthcare Solutions, Inc. | $13.17 | 07/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809610747 | CMS |
| AbbVie Inc. | $16.08 | 07/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795458233 | CMS |
| GENZYME CORPORATION | $20.21 | 07/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843637245 | CMS |
| Janssen Biotech, Inc. | $7.41 | 07/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788456932 | CMS |
| AbbVie Inc. | $23.66 | 07/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795458227 | CMS |
| AbbVie Inc. | $17.16 | 06/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795458221 | CMS |
| Lilly USA, LLC | $18.73 | 06/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819030311 | CMS |
| Janssen Biotech, Inc. | $4.50 | 06/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788456891 | CMS |
| Regeneron Healthcare Solutions, Inc. | $15.58 | 06/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809610745 | CMS |
| LEO Pharma Inc. | $12.76 | 06/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842238657 | CMS |
| AbbVie Inc. | $19.76 | 06/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795458215 | CMS |
| AbbVie Inc. | $15.82 | 06/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795458209 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $14.23 | 06/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849549179 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $12.88 | 06/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849549181 | CMS |
| AbbVie Inc. | $23.94 | 06/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795458203 | CMS |
| AbbVie Inc. | $12.17 | 05/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795458197 | CMS |
| Janssen Biotech, Inc. | $3.31 | 05/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788456927 | CMS |
| Novartis Pharmaceuticals Corporation | $14.63 | 05/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813134833 | CMS |
| AbbVie Inc. | $8.90 | 05/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795458191 | CMS |
| Regeneron Healthcare Solutions, Inc. | $16.67 | 05/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809610743 | CMS |
| Janssen Biotech, Inc. | $6.33 | 05/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788456887 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $848,779.58 | 205 |
| PY2024 | Principal investigator | $465,404.25 | 284 |
| PY2023 | Principal investigator | $512,761.61 | 145 |
| PY2022 | Recipient | $8.00 | 1 |
| PY2022 | Principal investigator | $318,333.10 | 76 |
| PY2021 | Recipient | $579.11 | 2 |
| PY2021 | Principal investigator | $303,603.63 | 109 |
| PY2020 | Recipient | $5,811.05 | 7 |
| PY2020 | Principal investigator | $509,738.55 | 72 |
| PY2019 | Recipient | $47,562.83 | 13 |
| PY2019 | Principal investigator | $1,244,974.63 | 84 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
284 records in PY2024
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $6,709.50 | 12/30/2024 | Non-covered Recipient Entity DS RESEARCH OF KENTUCKY LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1100763806 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000.00 | 12/17/2024 | Non-covered Recipient Entity DS RESEARCH OF KENTUCKY LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1125501030 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $150.00 | 12/17/2024 | Non-covered Recipient Entity DS RESEARCH OF KENTUCKY LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1125501032 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,764.57 | 12/12/2024 | Non-covered Recipient Entity DS RESEARCH OF KENTUCKY LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1125500580 |
| Principal investigator 1 | Incyte Corporation | $1,121.30 | 12/11/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689271 |
| Principal investigator 1 | Incyte Corporation | $2,080.00 | 12/11/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689583 |
| Principal investigator 1 | Incyte Corporation | $22.70 | 12/02/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689471 |
| Principal investigator 1 | Incyte Corporation | $45.80 | 12/02/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689479 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,714.00 | 12/02/2024 | Non-covered Recipient Entity DS RESEARCH OF KENTUCKY LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1079020908 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $3,382.19 | 11/21/2024 | Non-covered Recipient Entity DS RESEARCH OF KENTUCKY LLC | A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1156049725 |
| Principal investigator 1 | Incyte Corporation | $2,266.00 | 11/06/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689485 |
| Principal investigator 1 | Incyte Corporation | $1,230.50 | 11/06/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689487 |
| Principal investigator 1 | Incyte Corporation | $24.70 | 11/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689473 |
| Principal investigator 1 | Incyte Corporation | $22.90 | 11/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689475 |
| Principal investigator 1 | Incyte Corporation | $0.30 | 11/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689477 |
| Principal investigator 1 | Incyte Corporation | $4.90 | 11/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689481 |
| Principal investigator 1 | Incyte Corporation | $8.20 | 11/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689483 |
| Principal investigator 1 | Incyte Corporation | $8.20 | 11/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689493 |
| Principal investigator 1 | Incyte Corporation | $8.20 | 11/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689495 |
| Principal investigator 1 | Incyte Corporation | $8.20 | 11/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689497 |
| Principal investigator 1 | Incyte Corporation | $16.20 | 11/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689517 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,989.00 | 11/01/2024 | Non-covered Recipient Entity DS RESEARCH OF KENTUCKY LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1079020916 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,000.00 | 10/25/2024 | Non-covered Recipient Entity DS RESEARCH OF KENTUCKY LLC | A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-to-Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1125498799 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $20,014.20 | 10/16/2024 | Non-covered Recipient Entity Scott Health Services | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1151794118 |
| Principal investigator 1 | Incyte Corporation | $1,172.80 | 10/11/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689489 |
| Principal investigator 1 | Incyte Corporation | $1,565.00 | 10/11/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689491 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $5,750.00 | 10/04/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1156049455 |
| Principal investigator 1 | ABBVIE INC. | $11,035.00 | 10/03/2024 | Non-covered Recipient Entity DS RESEARCH OF KENTUCKY LLC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1100745546 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,460.00 | 10/03/2024 | Non-covered Recipient Entity DS RESEARCH OF KENTUCKY LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1079020910 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $551.95 | 09/19/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1156049341 |
| Principal investigator 1 | Incyte Corporation | $2,402.00 | 09/18/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689389 |
| Principal investigator 1 | Incyte Corporation | $928.70 | 09/18/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689395 |
| Principal investigator 1 | Incyte Corporation | $1,604.00 | 09/18/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689397 |
| Principal investigator 1 | ABBVIE INC. | $11,040.00 | 09/04/2024 | Non-covered Recipient Entity DS RESEARCH OF KENTUCKY LLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1100740116 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 09/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689423 |
| Principal investigator 1 | Incyte Corporation | $12.15 | 09/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689425 |
| Principal investigator 1 | Incyte Corporation | $4.24 | 09/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689435 |
| Principal investigator 1 | Incyte Corporation | $160.30 | 09/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689441 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 09/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689447 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 09/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689453 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 09/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689457 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 09/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689459 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 09/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689555 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 09/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689595 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 09/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689597 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 09/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689599 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,581.00 | 09/02/2024 | Non-covered Recipient Entity DS RESEARCH OF KENTUCKY LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1079020920 |
| Principal investigator 1 | Incyte Corporation | $1,477.00 | 08/14/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689387 |
| Principal investigator 1 | Incyte Corporation | $2,266.00 | 08/14/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689499 |
| Principal investigator 1 | Incyte Corporation | $1,619.00 | 08/14/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689519 |
| Principal investigator 1 | Incyte Corporation | $793.10 | 08/14/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689557 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $2,441.21 | 08/08/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1156049217 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,772.00 | 08/05/2024 | Non-covered Recipient Entity DS RESEARCH OF KENTUCKY LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1079020918 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $165.52 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127883809 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $165.52 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127883813 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $212.52 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127883817 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $177.22 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127883821 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $177.22 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127883826 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $177.22 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127883830 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $177.22 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127883834 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $212.52 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127883838 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $212.52 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127883842 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $177.22 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127883847 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $177.22 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127883851 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $177.22 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127883855 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $177.22 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127883859 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $212.52 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127883864 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $212.52 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127883868 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $177.22 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127883872 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $177.22 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127883876 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $177.22 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127883880 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $177.22 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127883884 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $212.52 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127885201 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $35.00 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127885206 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $35.00 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127885210 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $165.52 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127887201 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $165.52 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127887205 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $212.52 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127887209 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $177.22 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127887213 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $177.22 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127887217 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $177.22 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127887222 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $177.22 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127887226 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $212.52 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127887230 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $212.52 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127887234 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $177.22 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127887239 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $177.22 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127887243 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $177.22 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127887247 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $177.22 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127887252 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $212.52 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127887256 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $212.52 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127887260 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $177.22 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127887264 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $177.22 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127887269 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $177.22 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127887273 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $177.22 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127887277 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $212.52 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127888588 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $35.00 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127888592 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $35.00 | 08/02/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127888596 |
| Principal investigator 1 | Incyte Corporation | $0.93 | 08/01/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689413 |
| Principal investigator 1 | Incyte Corporation | $16.18 | 08/01/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689415 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 08/01/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689417 |
| Principal investigator 1 | Incyte Corporation | $186.81 | 08/01/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689419 |
| Principal investigator 1 | Incyte Corporation | $125.95 | 08/01/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689513 |
| Principal investigator 1 | Amgen Inc. | $1,968.00 | 07/25/2024 | Non-covered Recipient Entity DS RESEARCH | HORIZON P3 AD Monotherapy Induction | No dispute reported | 06/30/2026 | 1096310829 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,851.95 | 07/25/2024 | Non-covered Recipient Entity DS RESEARCH OF KENTUCKY LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1125494465 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $14,170.50 | 07/23/2024 | Non-covered Recipient Entity Scott Health Services | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1151794116 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $177.22 | 07/20/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127878412 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $177.22 | 07/20/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127878416 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $212.52 | 07/20/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127878421 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $178.98 | 07/20/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127878425 |
| Principal investigator 1 | Incyte Corporation | $2,080.00 | 07/10/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689269 |
| Principal investigator 1 | Incyte Corporation | $1,565.00 | 07/10/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689391 |
| Principal investigator 1 | Incyte Corporation | $1,672.00 | 07/10/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689393 |
| Principal investigator 1 | Incyte Corporation | $876.80 | 07/10/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689469 |
| Principal investigator 1 | Amgen Inc. | $750.00 | 07/09/2024 | Non-covered Recipient Entity DS RESEARCH | P2A DAX in Moderate-to-Severe AA | No dispute reported | 06/30/2026 | 1096312217 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $974.03 | 07/05/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1156048969 |
| Principal investigator 1 | Incyte Corporation | $7.29 | 07/05/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689399 |
| Principal investigator 1 | Incyte Corporation | $21.87 | 07/05/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689401 |
| Principal investigator 1 | Incyte Corporation | $22.90 | 07/05/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689403 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 07/05/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689405 |
| Principal investigator 1 | Incyte Corporation | $4.86 | 07/05/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689407 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 07/05/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689409 |
| Principal investigator 1 | Incyte Corporation | $62.27 | 07/05/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689411 |
| Principal investigator 1 | Incyte Corporation | $59.13 | 07/05/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689421 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 07/05/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689455 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 07/05/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689461 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 07/05/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689463 |
| Principal investigator 1 | Incyte Corporation | $4.86 | 07/05/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689465 |
| Principal investigator 1 | Incyte Corporation | $4.86 | 07/05/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689467 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 07/05/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689561 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 07/05/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689563 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 07/05/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689565 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 07/05/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689567 |
| Principal investigator 1 | Incyte Corporation | $4.12 | 07/02/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689427 |
| Principal investigator 1 | Incyte Corporation | $3.18 | 07/02/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689429 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 07/02/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689431 |
| Principal investigator 1 | Incyte Corporation | $8.24 | 07/02/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689433 |
| Principal investigator 1 | Incyte Corporation | $11.66 | 07/02/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689437 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 07/02/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689439 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 07/02/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689443 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 07/02/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689445 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 07/02/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689449 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 07/02/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689451 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 07/02/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689575 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 07/02/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689577 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,593.00 | 06/27/2024 | Non-covered Recipient Entity DS RESEARCH OF KENTUCKY LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1079020912 |
| Principal investigator 1 | Incyte Corporation | $2,402.00 | 06/07/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689263 |
| Principal investigator 1 | Incyte Corporation | $1,565.00 | 06/07/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689267 |
| Principal investigator 1 | Incyte Corporation | $1,672.00 | 06/07/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689337 |
| Principal investigator 1 | Incyte Corporation | $1,477.00 | 06/07/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689347 |
| Principal investigator 1 | Incyte Corporation | $474.20 | 06/07/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689381 |
| Principal investigator 1 | Incyte Corporation | $2,402.00 | 06/07/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689383 |
| Principal investigator 1 | Incyte Corporation | $1,604.00 | 06/07/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689515 |
| Principal investigator 1 | Incyte Corporation | $1,983.00 | 06/07/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689559 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 06/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689349 |
| Principal investigator 1 | Incyte Corporation | $0.62 | 06/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689351 |
| Principal investigator 1 | Incyte Corporation | $22.90 | 06/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689357 |
| Principal investigator 1 | Incyte Corporation | $59.13 | 06/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689359 |
| Principal investigator 1 | Incyte Corporation | $98.72 | 06/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689361 |
| Principal investigator 1 | Incyte Corporation | $2.79 | 06/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689363 |
| Principal investigator 1 | Incyte Corporation | $97.08 | 06/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689365 |
| Principal investigator 1 | Incyte Corporation | $62.27 | 06/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689521 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,549.00 | 06/04/2024 | Non-covered Recipient Entity DS RESEARCH OF KENTUCKY LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1079020914 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,543.43 | 06/03/2024 | Non-covered Recipient Entity DS RESEARCH OF KENTUCKY LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1125492172 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $1,750.03 | 05/30/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1156048759 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $18,723.25 | 05/29/2024 | Non-covered Recipient Entity Dermatology Specialists Research | A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1123476976 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $1,084.01 | 05/16/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1156048721 |
| Principal investigator 1 | Incyte Corporation | $54.76 | 05/06/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689367 |
| Principal investigator 1 | Incyte Corporation | $57.25 | 05/06/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689369 |
| Principal investigator 1 | Incyte Corporation | $64.72 | 05/06/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689371 |
| Principal investigator 1 | Incyte Corporation | $135.40 | 05/06/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689373 |
| Principal investigator 1 | Incyte Corporation | $59.13 | 05/06/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689375 |
| Principal investigator 1 | Incyte Corporation | $62.27 | 05/06/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689377 |
| Principal investigator 1 | Incyte Corporation | $24.68 | 05/06/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689379 |
| Principal investigator 1 | Incyte Corporation | $24.68 | 05/06/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689505 |
| Principal investigator 1 | Incyte Corporation | $11.45 | 05/06/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689509 |
| Principal investigator 1 | Incyte Corporation | $2,039.40 | 05/03/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689353 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $18,116.10 | 04/23/2024 | Non-covered Recipient Entity Scott Health Services | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1151794114 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,800.00 | 04/23/2024 | Non-covered Recipient Entity DS RESEARCH OF KENTUCKY LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1125490149 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000.00 | 04/23/2024 | Non-covered Recipient Entity DS RESEARCH OF KENTUCKY LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1125490157 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $755.00 | 04/23/2024 | Non-covered Recipient Entity DS RESEARCH OF KENTUCKY LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1125490161 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $13,148.33 | 04/23/2024 | Non-covered Recipient Entity DS RESEARCH OF KENTUCKY LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1125490171 |
| Principal investigator 1 | GENZYME CORPORATION | $7,246.99 | 04/22/2024 | Non-covered Recipient Entity Scott Health Services Llc Ds Research | POC - Atopic dermatitis | No dispute reported | 06/30/2026 | 1128709569 |
| Principal investigator 1 | GENZYME CORPORATION | $675.00 | 04/22/2024 | Non-covered Recipient Entity Scott Health Services Llc Ds Research | POC - Atopic dermatitis | No dispute reported | 06/30/2026 | 1128709571 |
| Principal investigator 1 | Amgen Inc. | $22,100.00 | 04/19/2024 | Non-covered Recipient Entity DS RESEARCH | ASCEND P3 AD Extension | No dispute reported | 06/30/2026 | 1096309173 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $451.33 | 04/11/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1156048595 |
| Principal investigator 1 | CSL Behring | $872.00 | 04/05/2024 | Non-covered Recipient Entity Scott Health Services, LLC | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) | No dispute reported | 06/30/2026 | 1142326024 |
| Principal investigator 1 | CSL Behring | $1,238.00 | 04/05/2024 | Non-covered Recipient Entity Scott Health Services, LLC | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) | No dispute reported | 06/30/2026 | 1142326026 |
| Principal investigator 1 | CSL Behring | $235.00 | 04/05/2024 | Non-covered Recipient Entity Scott Health Services, LLC | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) | No dispute reported | 06/30/2026 | 1142326028 |
| Principal investigator 1 | CSL Behring | $5,000.00 | 04/05/2024 | Non-covered Recipient Entity Scott Health Services, LLC | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) | No dispute reported | 06/30/2026 | 1142326030 |
| Principal investigator 1 | CSL Behring | $342.00 | 04/05/2024 | Non-covered Recipient Entity Scott Health Services, LLC | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) | No dispute reported | 06/30/2026 | 1142326032 |
| Principal investigator 1 | CSL Behring | $1,492.00 | 04/05/2024 | Non-covered Recipient Entity Scott Health Services, LLC | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) | No dispute reported | 06/30/2026 | 1142326034 |
| Principal investigator 1 | CSL Behring | $359.00 | 04/05/2024 | Non-covered Recipient Entity Scott Health Services, LLC | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) | No dispute reported | 06/30/2026 | 1142326036 |
| Principal investigator 1 | CSL Behring | $3,497.00 | 04/05/2024 | Non-covered Recipient Entity Scott Health Services, LLC | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) | No dispute reported | 06/30/2026 | 1142326038 |
| Principal investigator 1 | Eli Lilly and Company | $3,097.00 | 04/05/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | Not supplied | No dispute reported | 06/30/2026 | 1137367351 |
| Principal investigator 1 | Incyte Corporation | $1,477.00 | 04/05/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689355 |
| Principal investigator 1 | Incyte Corporation | $1,181.60 | 04/05/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689385 |
| Principal investigator 1 | Incyte Corporation | $45.80 | 04/02/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689339 |
| Principal investigator 1 | Incyte Corporation | $91.60 | 04/02/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689341 |
| Principal investigator 1 | Incyte Corporation | $0.93 | 04/02/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689343 |
| Principal investigator 1 | Incyte Corporation | $1.24 | 04/02/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689345 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 04/02/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689501 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 04/02/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689503 |
| Principal investigator 1 | Acrotech Biopharma Inc. | $40,387.50 | 03/28/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | 246-13651-302 | No dispute reported | 06/30/2026 | 1147107936 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $2,084.36 | 03/21/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1156048521 |
| Principal investigator 1 | GENZYME CORPORATION | $1,600.00 | 03/18/2024 | Non-covered Recipient Entity Scott Health Services Llc Ds Research | POC - Atopic dermatitis | No dispute reported | 06/30/2026 | 1128709567 |
| Principal investigator 1 | Kiniksa Pharmaceuticals International, plc | $3,074.47 | 03/18/2024 | Non-covered Recipient Entity Associates In Dermatology | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 1154868594 |
| Principal investigator 1 | Incyte Corporation | $1,477.00 | 03/13/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689325 |
| Principal investigator 1 | Incyte Corporation | $1,200.60 | 03/13/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689529 |
| Principal investigator 1 | Incyte Corporation | $1,565.00 | 03/13/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689545 |
| Principal investigator 1 | Incyte Corporation | $14.58 | 03/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689285 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 03/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689293 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 03/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689569 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 03/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689571 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 03/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689573 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,204.28 | 03/01/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127875873 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,014.22 | 03/01/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127875877 |
| Principal investigator 1 | Eli Lilly and Company | $163.50 | 02/08/2024 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS RESEARCH | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1137357815 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $3,252.02 | 02/08/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1156048357 |
| Principal investigator 1 | Incyte Corporation | $1,983.00 | 02/07/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689257 |
| Principal investigator 1 | Incyte Corporation | $1,477.00 | 02/07/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689327 |
| Principal investigator 1 | Incyte Corporation | $1,815.80 | 02/07/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689329 |
| Principal investigator 1 | Incyte Corporation | $0.62 | 02/02/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689273 |
| Principal investigator 1 | Incyte Corporation | $22.90 | 02/02/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689291 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 02/02/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689295 |
| Principal investigator 1 | Incyte Corporation | $98.72 | 02/02/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689315 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $19,576.60 | 02/01/2024 | Non-covered Recipient Entity Scott Health Services | A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1151794122 |
| Principal investigator 1 | Acrotech Biopharma Inc. | $3,490.00 | 01/25/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | 246-13651-301 | No dispute reported | 06/30/2026 | 1147107720 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $750.00 | 01/25/2024 | Non-covered Recipient Entity Scott Health Services | A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1151794120 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $21,231.90 | 01/19/2024 | Non-covered Recipient Entity Scott Health Services | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1151794112 |
| Principal investigator 1 | Acrotech Biopharma Inc. | $8,056.20 | 01/18/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | 246-13651-301 | No dispute reported | 06/30/2026 | 1147107704 |
| Principal investigator 2 | Arcutis Biotherapeutics, Inc. | $400.00 | 01/15/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES, LLC | A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis | No dispute reported | 06/30/2026 | 1121031688 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,004.28 | 01/13/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC DBA DS RESEARCH | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1127874747 |
| Principal investigator 1 | Eli Lilly and Company | $40,335.75 | 01/09/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1137366319 |
| Principal investigator 1 | Acrotech Biopharma Inc. | $1,550.00 | 01/04/2024 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | 246-13651-301 | No dispute reported | 06/30/2026 | 1147107638 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689259 |
| Principal investigator 1 | Incyte Corporation | $123.40 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689261 |
| Principal investigator 1 | Incyte Corporation | $19.44 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689265 |
| Principal investigator 1 | Incyte Corporation | $2.17 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689275 |
| Principal investigator 1 | Incyte Corporation | $1.86 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689277 |
| Principal investigator 1 | Incyte Corporation | $2.79 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689279 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689281 |
| Principal investigator 1 | Incyte Corporation | $6.51 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689283 |
| Principal investigator 1 | Incyte Corporation | $21.87 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689287 |
| Principal investigator 1 | Incyte Corporation | $19.44 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689289 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689297 |
| Principal investigator 1 | Incyte Corporation | $45.80 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689299 |
| Principal investigator 1 | Incyte Corporation | $51.03 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689301 |
| Principal investigator 1 | Incyte Corporation | $48.60 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689303 |
| Principal investigator 1 | Incyte Corporation | $59.13 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689305 |
| Principal investigator 1 | Incyte Corporation | $62.27 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689307 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689309 |
| Principal investigator 1 | Incyte Corporation | $74.04 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689311 |
| Principal investigator 1 | Incyte Corporation | $80.90 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689313 |
| Principal investigator 1 | Incyte Corporation | $123.40 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689317 |
| Principal investigator 1 | Incyte Corporation | $226.52 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689319 |
| Principal investigator 1 | Incyte Corporation | $206.10 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689321 |
| Principal investigator 1 | Incyte Corporation | $311.35 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689323 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689331 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689333 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689335 |
| Principal investigator 1 | Incyte Corporation | $9.72 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689507 |
| Principal investigator 1 | Incyte Corporation | $135.40 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689511 |
| Principal investigator 1 | Incyte Corporation | $64.72 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689523 |
| Principal investigator 1 | Incyte Corporation | $64.72 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689525 |
| Principal investigator 1 | Incyte Corporation | $64.72 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689527 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689531 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689533 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689535 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689537 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689539 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689541 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689543 |
| Principal investigator 1 | Incyte Corporation | $2.48 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689547 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689549 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689551 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689553 |
| Principal investigator 1 | Incyte Corporation | $103.05 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689579 |
| Principal investigator 1 | Incyte Corporation | $54.76 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689581 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689585 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689587 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689589 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689591 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 01/04/2024 | Non-covered Recipient Entity DERMATOLOGIST SPECIALIST | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1134689593 |
| Principal investigator 1 | Amgen Inc. | $11,057.93 | 01/03/2024 | Non-covered Recipient Entity DS RESEARCH | ASCEND P3 AD Extension | No dispute reported | 06/30/2026 | 1096309175 |